Midwest Kidney Network Recommended Treatment Goals 2021

Midwest Kidney Network's annual recommended treatment goals are based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, the Dialysis Facility Report (DFR), and the performance standards identified in the Quality Incentive Program (QIP) where applicable. Other goals are based on available evidence-based guidelines.

We provide these improvement goals as assistance to dialysis facilities for their use in quality improvement and with meeting the QIP performance standards. The goals apply to the facility's permanent adult dialysis population. Throughout this document, <u>mean value</u> refers to the average of the <u>last</u> monthly value for 12 months.

Anemia Management

- Facilities should dose ESAs to maximize the percent of patients with hemoglobin concentration 9 11.5 gm/dL¹
- Standardized Transfusion Rate (STrR) will be as expected as or better than expected.

Dialysis Adequacy

97.6% of all dialysis patients will achieve a Kt/V ≥ 1.2 (HD) or ≥ 1.7 (PD).

National Healthcare Safety Network (NHSN)

- Standardized Infection Ratio will be as expected or less than expected.
- Facility will report 12 months of event data into NHSN.

Vascular Access

- If ≤ 11% catheter in use for ≥ 90 days: Facility should maintain or reduce the percent of 90 day catheters
- If > 11% but ≤ 15%: Facility goal is to achieve 11% or less 90-day catheters.
- If > 15% catheters in use for ≥ 90 days: Facility goal is to reduce percent of 90-day catheters by a
 percent assigned in the Catheter Last goal report.

Nutritional Status

• \geq 80% of hemodialysis patients will have mean serum albumin \geq the lower limit of normal (LLN), and \geq 60% of peritoneal dialysis patients will have mean serum albumin \geq the lower limit of normal (LLN)

Bone and Mineral Metabolism

- ≥ 65% of dialysis patients (HD and PD) will have a mean serum phosphorus of ≤ 5.5 mg/dL
- < 10% of patients will have mean serum phosphorus of > 8 mg/dL
- ≤ 0.5% of dialysis patients (HD and PD) will have a mean uncorrected serum calcium concentration of > 10.2 mg/dL.
- 100% of patients will have PTH monitored at least every 3 months

¹ Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter., Suppl 2012: 2: 279-355 (Guidelines 3.4.3 and 3.5.1)

Midwest Kidney Network Recommended Treatment Goals 2021

Immunization

- \geq 80% of patients will receive vaccine for COVID-19 when it becomes available
- ≥ 90% of patients will receive immunization for influenza
- ≥ 80% of patients will receive immunization for pneumonia
- ≥ 90% of patients without natural immunity will receive immunization for hepatitis B
- ≥ 90% of dialysis personnel will be immunized for influenza

Advance Care Planning

≥ 95% of patients will have documentation that advance care planning discussions were conducted within 6 months of initiating dialysis

Kidney Transplant Referral

 \geq 95% of patients will be assessed by the interdisciplinary dialysis team for kidney transplant candidacy or referral within 4 months of initiating dialysis as demonstrated by medical record documentation

Home Dialysis Referral

≥ 95% of patients will be assessed by the interdisciplinary dialysis team for home dialysis candidacy or referral within 4 months of initiating dialysis as demonstrated by medical record documentation

In-center Hemodialysis Consumer Assessment of Healthcare Providers and Systems

- ICH-CAHPS survey is offered to patients semi-annually using a third party, CMS-approved vendor
- ICH-CAHPS survey results equal to or greater than the 50th percentile for 2020

Assessment of Depression and Follow-up

- ≥ 95% of eligible patients will be assessed for depression using a validated tool at least annually and documented in CROWNWeb
- ≥ 95% of eligible patients scoring positive for depression will be offered follow-up treatment documented in CROWNWeb